Treatment of resistant hypertension

Minerva Cardioangiologica

Volumn 57, Issue 6, 2009, Pages 787-811

  Czarina Acelajado, M ^a   Calhoun, D A ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Diagnosis ; Hypertension; Pharmacology; Therapy

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALIZAPRIDE; AMILORIDE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; CYCLOSPORIN; DARUSENTAN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; KETOCONAZOLE; LISINOPRIL; METOCLOPRAMIDE; MINERALOCORTICOID; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ALCOHOL CONSUMPTION; ANGINA PECTORIS; ARTERY DISEASE; BLOOD PRESSURE REGULATION; BREAST AUGMENTATION; BREAST TENDERNESS; CARDIOVASCULAR RISK; CATHETER ABLATION; CLINICAL TRIAL; CUSHING SYNDROME; DROWSINESS; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESISTANCE; DRUG WITHDRAWAL; FLUID RETENTION; HEART FAILURE; HEART INFARCTION; HIGH SODIUM INTAKE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; LIFESTYLE MODIFICATION; OBESITY; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PROGNOSIS; PROPHYLAXIS; REISISTANT HYPERTENSION; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP APNEA SYNDROME; SODIUM RESTRICTION; STROKE; URINARY FREQUENCY; WHITE COAT HYPERTENSION; XEROSTOMIA;

ADRENAL GLAND NEOPLASMS; ADULT; AFRICAN AMERICANS; AGED; AMBULATORY CARE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; CHLORTHALIDONE; CLINICAL TRIALS AS TOPIC; DIURETICS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; LIFE STYLE; MALE; MEDICATION ADHERENCE; OBESITY; PHEOCHROMOCYTOMA; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROGNOSIS; RENAL ARTERY OBSTRUCTION; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; SODIUM CHLORIDE SYMPORTER INHIBITORS; TIME FACTORS; UNITED STATES;

EID: 77949651015     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. American Heart Association Scientific Statement Resistant Hypertension: diagnosis, evaluation, and treatment. Hypertension 2008;51:1403-19.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. JAMA 2003;289:2560-72.
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
4. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control - continued disparities in adults: United States, 2005-2006. NCHS data brief Hyattsville, MD: National Center for Health Statistics; 2008. p. 1-8.
5. McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci 2009;64A:256-63.
6. Suh D-C, Kim C-M, Choi I-S, Plauschinat CA, Barone JA. Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States 1988-2004. J Hypertens 2009: 1908-16.
7. Snyder JJ, Collins AJ. KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD Population: National Health and Nutrition Examination Survey 1999-2004. Am J Nephrol 2009;30:44-54.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
9. Cushman WC, Ford CE, Einhorn PT, Wright JT Jr, Preston RA, Davis BR et al. for the ALLHAT Collaborative Research Group. Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2008;10:751-60.
10. Egan BM, Zhao Y, Rehman SU, Brzezinski WA, Clyburn B, Basile JN et al. Treatment resistant hypertension in a community-based practice network. J Clin Hypertens 2009;OR-12:A6 (abstract).
11. Ma J, Lee K-V, Stafford RS. Uncomplicated hypertension between 1993 and 2004. Hypertension 2006;48:846-52.
12. McAdam-Marx C, Ye X, Sung JC, Brizner DI, Kahler KH. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Ther 2009;3:1116-23.
13. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, Leung RST, Bradley TD. High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens 2001;19:2271-7.
14. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001;19:2063-70.
15. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit 2003;8:181-5.
16. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant and true resistant hypertension. Am J Hypertens 2005;18:1422-8.
17. Isaksson H, Ostergren J. Prognosis in therapy-resistant hypertension. J Intern Med 1994;236:643-9.
18. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Rocella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000;36:594-9.
19. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH et al. for the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002;4:393-404.
20. Lloyd-Jones DM, Evans JC, Larson MG, Levy D. Treatment and control of hypertension in the community: a prospective analysis. Hypertension 2002;40:640-6.
21. Lacchini R, Sabha M, Coeli FB, Bavero FF, Yugar-Toledo J, Izidoro-Toledo TC et al. T allele of -344C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension. Hypertens Res 2009;32:159-62.
22. Cruz-González I, Corral E, Sánchez-Ledesma M, Sánchez-Rodríguez, Martín-Luengo C, González- Sarmiento R. Association between -T786C NOS3 polymorphism and resistant hypertension: a prospective study. BMC Cardiovascular Disorders 2009:9:35.
23. Cruz-González I, Corral E, Sánchez-Ledesma M, Sánchez-Rodríguez, Martín-Luengo C, González- Sarmiento R. An association between resistant hypertension and the null GSTM1 genotype. J Hum Hypertens 2009;23:556-8.
24. Hannila-Handelberg T, Kontula K, Tikkanen I, Tikkanen T, Fyhrquist F, Helin K et al. Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to the plasma renin and aldosterone levels in essential hypertension. BMC Medical Genetics 2005;6:4.
25. Givens RC, Lin YS, Dowling ALS, Thummel KE, Lamba JK, Schuetz EG et al. CYP3A5 gentoype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003;95:1297-300.
26. Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC et al. Association between CYP3A5 genotype and blood pressure. Hypertension 2005;45:294-8.
27. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41-6.
28. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: A comparison of two university-based cohorts. Am J Hypertens 2005;18:615-26.
29. De Souza WA, Yugar-Toledo JC, Bergsten-Mendes G, Sabha M, Moreno H. Effect of pharmaceutical care on blood pressure and health-related quality of life in patients with resistant hypertension. Am J Health-Syst Pharm 2007;64:1955-61.
30. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998;31:712-718.
31. Pimenta E, Gaddam KK, Pratt-Ubunama MK, Nishizaka MK, Cofield SS, Oparil S et al. Aldosterone excess and resistance to 24-hour blood pressure control. J Hypertens 2007;25:2131-7.
32. Salles GF, Cardoso CRL, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressure in resistant hypertension. Arch Intern Med 2008;168:2340-6.
33. Bramlage P, Pittrow D, Wittchen H-U, Kirch W, Boehler S, Lehnert H et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004;17:904-10.
34. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003;41:625-33.
35. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ et al. Effects of dietary sodium restriction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009;54:475-81.
36. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta ES, Aban I, Oparil S et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008;168:1159-64.
37. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001;38:1112-17.
38. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? Ann Intern Med 1994;121:289-300.
39. Whelton A, White WB, Bello AE, Puma JA, Fort GF and the SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients?65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.
40. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med 1987;107:628-35.
41. Conlin PR, Moore TJ, Swartz SL, Barr E, Gazdick L, Fletcher C et al. Effect of indomediacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000;36:461-5.
42. Ernst E. The risk-benefit profile of commonly used herbal therapies: ginkgo, St John's wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med 2002;136:42-53.
43. Mansoor GA. Herbs and alternative therapies in the hypertension clinic. Am J Hypertens 2001;14:971-5.
44. Walker BR, Edwards CR. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am 1994;23:359-77.
45. Dellow EL, Unwin RJ, Honour JW. Pontefract cakes can be bad for you: refractory hypertension and liquorice excess. Nephrol Dial Transplant 1999;14:218-20.
46. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG; for the Sleep Heart Health Study. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 2000;283:1829-36.
47. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Eng J Med 2000;342:1378-84.
48. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension Chest 2007;131:453-9.
49. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing between middle-aged adults. NEJM 1993;328:1230-5.
50. Worsnop CJ, Naughton MT, Barter CE, Morgan TO, Anderson AI, Pierce RJ. The prevalence of obstructive sleep apnea in hypertensives. Am J Resp Crit Care Med 1998;157:111-5.
51. Goncalves SC, Martinez D, Gus M, de Abreu-Silva EO, Bertoluci C et al. Obstructive sleep apnea and resistant hypertension: a case-control study. CHEST 2007;132:1858-62.
52. Grote L, Hedner J, Peter JH. Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. J Hypertens 2000;18:679-85.
53. Lavie P, Hoffstein V. Sleep apnea syndrome: a possible contributing factor to resistant hypertension. Sleep 2001;24:721-5.
54. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanism in obstructive sleep apnea. J Clin Invest 1995;96:1897-904.
55. Grassi GG, Facchini A, Trevano FQ, Dell'Oro R, Arenare F, Tana F et al. Obstructive sleep apnea-dependent and -independent adrenergic activation of obesity. Hypertension 2005;46:321-5.
56. Lavie L, Hefetz A, Luboshitzky R, Lavie P. Plasma levels of nitric oxide and L-arginine in sleep apnea patients: effects of nCPAP treatment. J Mol Neurosci 2003;21:57-63.
57. Duchna H-W, Orth M, Schultze-Werninghaus G, Guilleminault C, Stoohs RA. Long-term effects of nasal continuous positive airway pressure on vasodilatory endothelial function in obstructive sleep apnea. Sleep Breath 2005;9:97-103.
58. Jelic S, Bartels MN, Mateika JH, Ngai P, DeMeersman RE, Basner RC. Arterial stiffness increases during obstructive sleep apneas. Sleep 2002;25:850-5.
59. Drager LF, Bortolotto LA, Lorenzi MC, Figueriredo AC, Krieger EM, Larenzi-Filho G. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005;172:613-8.
60. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2007;176:706-12.
61. Kitahara Y, Hattori N, Yokoyama A, Nakajima M, Kohno N. Effect of CPAP on brachial-ankle pulse wave velocity in patients with OSAHS: an open-labeled study. Respir Med 2006;100:2160-9.
62. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004;125:112-7.
63. Chiu KL, Ryan CM, Shiota S, Ruttanaumpawan P, Arzt M, Haight JS et al. Fluid shift by lower body positive pressure increases pharyngeal resistance in healthy subjects. Am J Respir Crit Care Med 2006;174:1378-83.
64. Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L et al. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest 2007;132:440-6.
65. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955;45:3-17.
66. Gordon RD, Stowasser M, Tunny JT, Klemm A, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994;21:315-8.
67. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montera J et al. Primary aldosteronism and hypertensive disease. Hypertension 2003;2:161-5.
68. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissman P. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002;40:892-6.
69. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001;37:699-705.
70. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004;22:2217-26.
71. trauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Human Hypertens 2003;17:349-52.
72. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005;8:805-12.
73. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-30.
74. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45.
75. Buckalew VM, Berg RL, Wang SR, Porush JG, Rauch S, Schulman G. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996;28:881-21.
76. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW et al. for The Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-84.
77. Saelen MG, Prøsch LK, Gudmundsdottir H, Dyrbekk D, Helge Hundert O, Arnesen E et al. Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function. Blood Press 2005;14:170-6.
78. Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney International 2006;69:967-73.
79. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994;12:609-15.
80. Crowley JJ, Santos RM, Peter RH, Puma JA, Schwab SJ, Phillips HR et al. Progression of renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J 1998;136:913-8.
81. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344:431-42.
82. Findling JW, Raff H. Screening and diagnosis of Cushing's syndrome. Endocrinol Metab Clin N Am 2005;34:385-482.
83. Magiakou MA, Smyrnaki P, Chrousos GP. Hypertension in Cushing's syndrome. Best Pract Res Clin Endocrinol Metab 2006;20:467-82.
84. Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage MO, Stewart PM et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol 2008;93:1526-40.
85. Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res 2008;40:329-37.
86. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007;50:417-23.
87. Haentjens P, Meerhaeghe AV, Moscariello A, De Weerdt S, Poppe K, Dupont A, Velkeniers B. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome. Arch Intern Med 2007;167:757-65.
88. Martinez-Garcia MA, Gomez-Aldaravi R, Soler-Cataluna JJ, Martinez TG, Bernacer-Alpera B, Roman-Sanchez P. Positive effect of CRAP treatment on the control of difficult-to-treat hypertension. Eur Respir J 2007;29:951-7.
89. Logan AG, Tkacova R, Perlikowski SM, Leung RS, Tisler A, Floras JS, Bradley TD. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur Respir J 2003;21:241-7.
90. Birrer M, Do DD, Mahler F, Triller J, Baumgartner I. Treatment of renal artery fibromuscular dysplasia with balloon angioplasty: a prospective follow-up study. Eur J Vasc Endovasc Surg 2002;23:146-52.
91. Taler SJ, Textor SC, Augustine JE. Resistant hypertension. Comparing hemodynamic management to specialist care. Hypertension 2002;39:982-8.
92. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10-years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990;82:1616-28.
93. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-8.
94. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding Perindopril as required versus atenolol adding benzoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
95. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-45.
96. Antonio Costa J, Rodilla E, Pérez-Lahiguera F, María Pascual J. Eplerenone in resistant hypertension with previous spironolactone intolerance. Med Clin (Barc) 2009;132:756-7.
97. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao O, Pratt JA. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005;46:481-7.
98. Cachofeiro V, Miana M, de Las Heras N, Martín-Fernández B, Ballesteros S, Fernández-Tresguerres J et al. Aldosterone and the vascular system. J Steroid Biochem Mol Biol 2008;109:331-5.
99. Townsend RR, DiPette DJ, Goodman R, Blumfield D, Cronin R, Gradman A et al. Combined alpha/beta blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther 1990;48:665-75.
100. Muxfeldt ES, Cardoso CRL, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med 2009;169:874-80.
101. Hermida RC, Ayala DE, Calvo C, Lopez JE, Mojon A, Fontao MJ et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 2005;46:1053-9.
102. Hermida RC, Smolensky MH. Chronotherapy of hypertension. Curr Opin Nephrol Hypertens 2004;13:501-5.
103. Epstein BJ. Efficacy and safety of darusentan: A novel endothelin receptor antagonist. Ann Pharmacother 2008;42:1060-9.
104. Weber MA, Black H, Bakris G et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomized, double-blind, placebo-controlled trial. Lancet 2009;374:1423-31.
105. Filippone JD, Bisognano JD. Baroreflex stimulation in the treatment of hypertension. Curr Opin Nephrol Hypertens 2007;16:403-8.
106. Illig KA, Levy M, Sanchez L, Trachiotis GD, Shanley C, Irwin E et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter Phase II Rheos feasibility trial. J Vasc Surg 2006;44:1213-8.
107. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowsky J, Bartus K et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81.
108. Bansal N, Tendler BE, White WB, Mansoor GA. Blood pressure control in the Hypertension Clinic. Am J Hypertens 2003;16:878-80.